- Home
- BCDA vs POLA Comparison
BCDA vs POLA Comparison
Compare BCDA & POLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCDA
- POLA
- Stock Information
- Founded
- BCDA N/A
- POLA 1979
- Country
- BCDA United States
- POLA United States
- Employees
- BCDA N/A
- POLA N/A
- Industry
- BCDA Biotechnology: Pharmaceutical Preparations
- POLA Industrial Machinery/Components
- Sector
- BCDA Health Care
- POLA Miscellaneous
- Exchange
- BCDA Nasdaq
- POLA Nasdaq
- Market Cap
- BCDA 11.0M
- POLA 5.6M
- IPO Year
- BCDA N/A
- POLA 2016
- Fundamental
- Price
- BCDA $1.99
- POLA $1.70
- Analyst Decision
- BCDA Strong Buy
- POLA
- Analyst Count
- BCDA 1
- POLA 0
- Target Price
- BCDA $25.00
- POLA N/A
- AVG Volume (30 Days)
- BCDA 51.3K
- POLA 8.9K
- Earning Date
- BCDA 08-12-2025
- POLA 08-13-2025
- Dividend Yield
- BCDA N/A
- POLA N/A
- EPS Growth
- BCDA N/A
- POLA N/A
- EPS
- BCDA N/A
- POLA N/A
- Revenue
- BCDA $3,000.00
- POLA $13,918,000.00
- Revenue This Year
- BCDA N/A
- POLA N/A
- Revenue Next Year
- BCDA N/A
- POLA N/A
- P/E Ratio
- BCDA N/A
- POLA N/A
- Revenue Growth
- BCDA N/A
- POLA 8.08
- 52 Week Low
- BCDA $1.63
- POLA $1.65
- 52 Week High
- BCDA $4.66
- POLA $4.90
- Technical
- Relative Strength Index (RSI)
- BCDA 51.13
- POLA 42.95
- Support Level
- BCDA $1.98
- POLA $1.67
- Resistance Level
- BCDA $2.45
- POLA $1.75
- Average True Range (ATR)
- BCDA 0.17
- POLA 0.05
- MACD
- BCDA 0.01
- POLA 0.01
- Stochastic Oscillator
- BCDA 53.19
- POLA 57.14
About BCDA BioCardia Inc.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).
About POLA Polar Power Inc.
Polar Power Inc is engaged in designing, manufacturing, and selling DC power generators, renewable energy, and cooling systems for applications in the telecommunications market and, to a lesser extent, in other markets, including military, electric vehicle, marine, and industrial. The company's products include DC generators, backup DC generators, hybrid power systems, Li-Ion battery systems, Marine DC generators, and others. The company's geographical presence is in the United States, Canada, Australia and South Pacific Islands, Asia, Europe and Middle East, United Kingdom, Other North America, South Africa, and others.